Tag: #PharmaTrends
-

FDA and HHS Announce Biosimilar Reform — No More Comparative Trials, Full Interchangeability Ahead
The U.S. FDA and HHS have announced a landmark reform to eliminate comparative efficacy trials for biosimilars, aiming to reduce development costs and expand patient access to affordable biologic medicines.